for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Ekso Bionics Holdings Inc

EKSO.OQ

Latest Trade

0.54USD

Change

0.02(+4.39%)

Volume

105,665

Today's Range

0.50

 - 

0.54

52 Week Range

0.49

 - 

2.55

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.52
Open
0.54
Volume
105,665
3M AVG Volume
9.99
Today's High
0.54
Today's Low
0.50
52 Week High
2.55
52 Week Low
0.49
Shares Out (MIL)
74.92
Market Cap (MIL)
38.72
Forward P/E
-1.99
Dividend (Yield %)
--

Next Event

Ekso Bionics Holdings Inc at Cantor Fitzgerald Global Healthcare Conference

Latest Developments

More

Ekso Bionics Posts Q2 Loss Per Share Of $0.04

Ekso Bionics Q1 Loss Per Share $0.10

Ekso Bionics Reports Fourth Quarter And 2018 Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Ekso Bionics Holdings Inc

Ekso Bionics Holdings, Inc., formerly PN Med Group, Inc., designs, develops and sells wearable bionic human exoskeletons that have applications in healthcare, industrial, military and consumer markets. The Company operates through two segments: Engineering Services and Medical. The Engineering Services segment is engaged in collaborative research and development service arrangements, technology license agreements and government grants where it uses its robotics domain knowledge in bionic exoskeletons to bid on and procure contracts and grants from entities, such as the National Science Foundation and the Defense Advanced Research Projects Agency. The Medical segment designs, engineers and manufactures exoskeletons for applications in the medical and military markets. The Company's exoskeleton systems are worn over the user's clothing. The exoskeleton systems serve various markets, which can be used both by able-bodied users, as well as by persons with physical disabilities.

Industry

Medical Equipment & Supplies

Contact Info

1414 Harbour Way S Ste 1201

+1.510.9841761

https://ir.eksobionics.com/

Executive Leadership

Steven A. Sherman

Executive Chairman of the Board

Jack Peurach

President, Chief Executive Officer, Director

John F. Glenn

Chief Financial Officer, Secretary

Matthias Stief

Managing Director

Bill Shaw

Chief Commercial Officer

Key Stats

2.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-2.050

2017

-0.920

2018

-0.460

2019(E)

-0.260
Price To Earnings (TTM)
--
Price To Sales (TTM)
3.04
Price To Book (MRQ)
7.16
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
71.58
LT Debt To Equity (MRQ)
28.40
Return on Investment (TTM)
-137.97
Return on Equity (TTM)
-84.98

Latest News

BRIEF-Ekso Bionics Q1 Loss Per Share $0.13

* Q1 REVENUE ROSE 75 PERCENT TO $2.5 MILLION Source text for Eikon: Further company coverage:

BRIEF-Ekso Bionics Holdings Q4 Revenue $2.5 Million

* EKSO BIONICS REPORTS FOURTH QUARTER AND YEAR END 2017 RESULTS

BRIEF-Ekso Bionics Announces Executive Leadership Changes

* EKSO BIONICS ANNOUNCES EXECUTIVE LEADERSHIP CHANGES; JACK PEURACH, CO-FOUNDER OF EKSO BIONICS, LONG-TIME BOARD MEMBER AND SEASONED EXECUTIVE APPOINTED PRESIDENT AND CHIEF EXECUTIVE OFFICER; CHARLES LI, PH. D. TO JOIN BOARD OF DIRECTORS

BRIEF-Ekso Bionics To Expand Clinical Trial Sites For Comparative Multicenter WISE Study

* EKSO BIONICS® TO EXPAND CLINICAL TRIAL SITES FOR COMPARATIVE MULTICENTER WISE STUDY

BRIEF-Ekso Bionic Partners With HASOMED To Launch Functional Electrical Stimulation For The EksoGT Exoskeleton

* EKSO BIONICS HOLDINGS INC - LAUNCH OF EKSOGT EXOSKELETON'S FUNCTIONAL ELECTRICAL STIMULATION INTERFACE CAPABILITY THROUGH A PARTNERSHIP WITH HASOMED Source text for Eikon: Further company coverage:

Ford, Ekso team up for 'bionic' auto workers

Robots have replaced many U.S. manufacturing workers, but new mechanical exoskeletons being tested by Ford Motor Co <F.N> may help factory workers to function like bionic people, reducing the physical damage of millions of repetitive tasks over many years.

BRIEF-Ekso Bionics holdings Q3 loss per share $0.18

* Q3 revenue $1.6 million Source text for Eikon: Further company coverage:

BRIEF-Ekso Bionics Holdings files for stock shelf of up to $25.7 mln

* Ekso bionics holdings inc files for stock shelf of up to $25.7 million – sec filing Source text for Eikon: (http://bit.ly/2y233AA) Further company coverage:

BRIEF-Ekso Bionics appoints Ted Wang to its board of directors

* Ekso Bionics Holdings Inc - wang will replace Dan Boren, who joined Ekso board in April 2013 and resigned effective September 19, 2017 Source text for Eikon: Further company coverage:

BRIEF-Ekso Bionics raises $34 mln in fully-financed rights offering

* Ekso Bionics Holdings Inc - Ekso raised $34.0 million of gross proceeds, including a $20.5 million investment by Puissance Capital Management

BRIEF-Ekso Bionics announces commencement of $34 million rights offering

* Ekso Bionics announces commencement of $34 million rights offering

BRIEF-Ekso Bionics reports second quarter 2017 financial results

* Q2 revenue $1.9 million Source text for Eikon: Further company coverage:

BRIEF-Ekso Bionics announces proposed $34 million rights offering

* Ekso Bionics announces proposed $34 million rights offering; committed investment from Puissance Capital Management to support rights offering

BRIEF-Ekso Bionics Holdings files for mixed shelf of up to $75 mln

* Ekso Bionics Holdings Inc files for mixed shelf of up to $75.0 million - sec filing Source text : http://bit.ly/2rQy8nt Further company coverage:

BRIEF-Ekso Bionics Holdings to reduce workforce by about 25 pct

* Ekso bionics announces cost reductions to lower operating expenses

BRIEF-Ekso Bionics reports Q1 revenue $1.4 million

* Qtrly loss per share $0.38 Source text for Eikon: Further company coverage:

BRIEF-Ekso Bionics announces pricing of $11.7 million financing

* Ekso Bionics Holdings - entered agreements with certain institutional investors providing for purchase, sale of 3.7 million shares of common stock for $3.14/share Source text for Eikon: Further company coverage:

BRIEF-Ekso Bionics Holdings to expand number of directors from 7 to 8

* Ekso Bionics Holdings- on March 21, board of directors of co voted to expand number of directors of company from seven to eight directors- sec filing Source text - http://bit.ly/2naI32V Further company coverage:

BRIEF-Ekso Bionics Q4 revenue $2.6 mln versus $1.9 mln

* Ekso Bionics reports fourth quarter and year end 2016 results

BRIEF-Ekso Bionics sees Q4 2016 revenue more than $2.5 mln

* Ekso Bionics announces preliminary results for fourth quarter and full year 2016 and update on WISE study; record Ekso GT Systems placed in North America

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up